Product
Telomelysin
1 clinical trial
1 indication
Indication
Esophagogastric AdenocarcinomaClinical trial
Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric AdenocarcinomaStatus: Completed, Estimated PCD: 2023-06-20